| Age, years |
|
| Median (range) |
73.9 (65−91) |
| Sex |
|
| Male |
57 (59.4%) |
| Eastern Cooperative Oncology Group (ECOG) performance status |
|
| 0−1 |
46 (47.9%) |
| 2−4 |
50 (52.1%) |
| Body mass index (BMI) |
|
| Median (range) |
23.2 (16.3−32.2) |
| Mini nutritional assessment short from (MNA-SF) score |
|
| Median (range) |
9 (4−13) |
| World Health Organization (WHO) classification |
|
| Acute myeloid leukemia (AML) with recurrent genetic abnormalities |
10 (10.4%) |
| AML with t (8;21) (q22; q22.1); RUNX1-RUNX1T1 |
4 (4.2%) |
| AML with inv (16) (p13.1q22) or t (16; 16) (p13.1; q22); CBFB-MYH11 |
1 (1.0%) |
| AML with inv (3) (q21.3q26.2) or t (3;3) (q21.3; q26.2); GATA2, MECOM |
1 (1.0%) |
| AML with mutated NPM1 |
4 (4.2%) |
| AML with myelodysplasia-related changes |
24 (25.0%) |
| Therapy-related myeloid neoplasms |
5 (5.2%) |
| AML, not otherwise specified |
57 (59.4%) |
| Risk groups |
|
| Favorable risk |
9 (9.4%) |
| Intermediate risk |
65 (67.7%) |
| Poor risk |
22 (22.9%) |
| Bone marrow (BM) blasts |
|
| Median (range) |
56% (20−97) |
| Peripheral blood (PB) blasts |
|
| Present |
60 (62.5%) |
| Median (range) |
7% (0−92%) |
|
White blood cells, 109/L
|
|
| Median (range) |
3.87 (0.51−176.44) |
| Hemoglobin, g/dL |
|
| Median (range) |
8.3 (3.5−11.9) |
|
Platelet, 103/mm3
|
|
| Median (range) |
58 (1−945) |
| Albumin, g/dL |
|
| Median (range) |
3.7 (2.3−4.8) |
| Creatinine, mg/dL |
|
| Median (range) |
1.0 (0.4−4.9) |
| CRP, mg/dL |
|
| Median (range) |
1.75 (0.03−62.5) |
| Ferritin, ng/mL |
|
| Median (range) |
585 (80−>10000) |
